Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)
Study Details
Study Description
Brief Summary
Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT). Prolonged neutropenia after remission induction chemotherapy (>10 days duration) and continuous immunosuppression in the context of prevention or therapy of graft versus host disease (GVHD) for HSCT recipients (first 100 days post-transplantation and thereafter if GVHD is present) are considered as periods at high risk of IMI.
Posaconazole prophylaxis is prescribed according to current guidelines to reduce the occurrence of IMI. Nevertheless, breakthrough IMI (bIMI), i.e. IMI occurring under mold-active prophylaxis, are still observed.
The investigators hypothesized that the epidemiology of bIMI (under posaconazole prophylaxis) differs from that of IMI occurring in the absence of mold-active antifungal prophylaxis. Because bIMI are rare events since the introduction of posaconazole prophylaxis, epidemiological data of bIMI are scarce.
This study aims to i) describe the epidemiology, clinical features, treatment and outcome of bIMI, ii) assess the causes of bIMI, iii) determine potential risk factors associated with the developllement of bIMI iv) assess the impact of bIMI on overall mortality.
Design
Retrospective and prospective, observational, case-control, multicenter, international study.
The retrospective part will enroll previously identified bIMI cases and control cases (1:2) over the last five years: October 1st 2015 to September 30st 2020.
The prospective part will enroll bIMI cases and control cases (1:2) occurring over a two-year period: October 1st 2020 to September 30st 2022.
Setting
The aim is to enroll 10 to 15 European centers with dedicated units for hematologic cancer patients. Currently, six centers have confirmed their participation (from Switzerland and Germany).
Study Population
Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis during induction, consolidation or re-induction chemotherapy or after HSCT.
Cases : patients receiving posaconazole prophylaxis for at least 7 days and diagnosed with bIMI proven or probable according to EORTC-MSGERC.
Controls: patients receiving posaconazole prophylaxis for at least 7 days, without diagnosis of bIMI possible, probable or proven according to EORTC-MSGERC.
The objective is to enroll about 100 bIMI cases and 200 controls.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| bIMI cases Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for: i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD). AND iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days. |
|
| Controls For each bIMI case, we will include 2 control cases fulfilling the following criteria: i) Receiving continuous posaconazole prophylaxis for at least 7 days ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay |
Outcome Measures
Primary Outcome Measures
- Epidemiological description of bIMI [At inclusion]
Assessment of the cause of bIMI (intrinsically resistant mold pathogen vs susceptible mold pathogen but insufficient posaconazole serum concentration vs unknown) Description of clinical features, treatment and outcome of bIMI
- Assessment of the risk factors of bIMI [At inclusion]
• Univariate and multivariate analyses of the parameters associated with an increased risk of bIMI (in particular, the association of a threshold of posaconazole concentration and bIMI) by comparison of bIMI cases with controls (posaconazole prophylaxis and no bIMI)
Secondary Outcome Measures
- Assessment of the impact of bIMI on overall mortality [6 weeks and 12 weeks after inclusion]
• Comparison of mortality rate (6 and 12 weeks) between bIMI and control cases.
- Assessment of factors influencing outcomes of bIMI [6 weeks and 12 weeks after inclusion]
• Univariate and multivariate analysis of predictors of mortality (6 and 12 weeks) among bIMI cases.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Cases:
Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:
- Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days)
OR
- Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).
AND
- Being diagnosed with proven or probable bIMI according to the EORTC-MSG classification (10) while on continuous posaconazole prophylaxis for at least 7 days.
- Controls:
For each bIMI case, we will include 2 control cases fulfilling the following criteria:
-
Receiving continuous posaconazole prophylaxis for at least 7 days
-
No diagnosis of proven, probable or possible IMI according to EORTC-MSG classification (10) during the entire hospital stay.
And matched to bIMI cases according to the following criteria:
-
Hospitalization in the same ward within the same year (+/- 12 months interval)
-
Same underlying condition related to hematologc cancer: a) HSCT within 100 days post-engraftment, b) HSCT > 100 days post-engraftment with intensified immunosuppressive regimen for severe GVHD, c) induction chemotherapy for acute myeloid or lymphoid leukemia, or myelodysplastic syndrome, d) other hematologic disorders (e.g. aplastic anemia) with prolonged neutropenia and/or immunosuppressive regimen.
Exclusion Criteria:
-
Patients with a diagnosis of possible IMI according to the EORTC-MSG classification.
-
Patients with a positive fungal biomarker in serum (e.g. galactomannan or beta-glucan) in the absence of clinical or radiological criteria of IMI according to the EORTC-MSG classification.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of Innsbruck | Innsbruck | Austria | ||
| 2 | University Hospital Cologne | Köln | Germany | ||
| 3 | Universitätsspital Basel | Basel | Switzerland | ||
| 4 | Inselspital Bern | Bern | Switzerland | ||
| 5 | Hôpital Cantonal de Fribourg | Fribourg | Switzerland | ||
| 6 | Hôpitaux Universitaires de Genève (HUG) | Geneva | Switzerland | ||
| 7 | Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne | Switzerland | ||
| 8 | Kantonsspital St.Gallen | Saint Gallen | Switzerland |
Sponsors and Collaborators
- Centre Hospitalier Universitaire Vaudois
Investigators
- Principal Investigator: Frederic Lamoth, Centre Hospitalier Universitaire Vaudois
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020-01719